Hodgkin Lymphoma Clinical Trials

• Age ≥18 years;

• Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria;

• Patient with any nodal mass ≥ than 10 cm can be included

• No previous treatment for Hodgkin lymphoma;

• ECOG performance status 0 to 2;

• Presence of FDG-avid lymphoma lesions on baseline PET scan;

• Subject understands and voluntarily signs the informed consent form approved by the Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures;

• Adequate organ and marrow function as defined below:

‣ absolute neutrophil count \> 1.0 x109/L

⁃ platelet count \> 75 x109/L

⁃ Total bilirubin \< 2 mg/dl without a pattern consistent with Gilbert's syndrome

⁃ Aspartate Transaminase and Alanine Transaminase (AST/ALT) \< 3.0 X institutional Upper Limits of Normality (ULN)

⁃ Creatinine within normal institutional limits or creatinine clearance \> 50 mL/min

• Women of childbearing potential must agree to use a highly effective method of contraception (oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) from the signature of informed consent until six months after the last dose of treatment;

• Men must agree to use a highly effective method of contraception (barrier contraception or abstinence, when this is in line with the usual lifestyle of the subject) from the signature of informed consent until six months after the last dose of treatment;

• Women of childbearing potential must have a negative serum pregnancy test at screening.